M Ken Kengatharan | Managing Partner, Atheneos Ventures and CEO
Auxesia Orion

M Ken Kengatharan, Managing Partner, Atheneos Ventures and CEO, Auxesia Orion

M. (Ken) Kengatharan, CEO, Auxesia Orion and Managing General Partner, Atheneos Ventures
Dr Kengatharan is a co-founder of several San Francisco bay area based biopharmaceutical companies where he held responsibilities in R&D and corporate development. He is currently President & CEO of Auxesia Orion and a member of the board of Renexxion. Previously he was President & CEO of Armetheon (renamed Espero Biopharma following a merger) and prior to that President & CSO of Altheos. He is the former Vice President,  Pre-Clinical R&D of Athenagen (re-named  CoMentis following a merger). He is also managing general partner at Atheneos Ventures (formerly Atheneos Capital), a San Francisco bay area based evergreen healthcare incubator fund focusing on opportunities in orphan drugs and rare diseases going forward.  During the last 17 years, Dr. Kengatharan has been critical to the development of multiple drug candidates (NCEs and re-purposed drugs) from concept to Phase 2/3. Since setting-up his first company in the late 1990s, with a great team and highly supportive investors in each case, he has been critical to setting-up multiple companies  and raising >$160MM in private equity and for closing partnership transactions in excess of $1bn in deal value. He has served on the boards of EPi3 (UK), Athenagen, Altheos, Armetheon, he has been an advisor/advisory board member at Spire-BioVentures, Cardinal Free Clinics (Stanford University School of Medicine), a mentor at University of California, San Francisco (UCSF)’s entrepreneurship program and a panel judge for the Stanford Business School’s Ignite Program. He trained as a cardiovascular pharmacologist in London and at Stanford after obtaining his PhD in pharmacology from the University of London. He obtained his MBA (with Distinction) from Durham University in England, where he focused on Biotech Finance and Entrepreneurship.


World Orphan Drug Congress USA 2018 - Conference Day Two @ 14:09

ROUNDTABLE 9: Unorthodox funding strategies - alternate but complimentary paths to funding orphan drug companies

back to speakers